2025年10月31日,由于股本不足,CERo治疗学公司丧失了Nasdaq公司的名单,导致暂停营业。 CERo Therapeutics lost its Nasdaq listing due to insufficient equity, triggering a suspension on Oct. 31, 2025.

CERo 治疗机构收到一项Nasdaq决定,由于未能满足250万美元的股东股权要求,拒绝其保留列名的请求,裁决可追溯至2025年4月22日。 CERo Therapeutics received a Nasdaq decision denying its request to maintain listing due to failing to meet the $2.5 million stockholders’ equity requirement, with the ruling retroactive to April 22, 2025. 该公司以前认为,在经过一轮融资和资产销售之后,它重新遵守了规定,但8月出售有价证券的贴现使股本低于门槛值。 The company had previously believed it regained compliance after a financing round and asset sales, but a discounted sale of marketable securities in August reduced equity below the threshold. Nasdaq听证会小组没有考虑CERo恢复合规的计划,其中包括从首选股票销售中获取225万美元,并寻求再获得475万美元。 The Nasdaq Hearings Panel did not consider CERo’s plan to restore compliance, which includes securing $2.25 million from preferred stock sales and seeking $4.75 million more. 该公司计划对这一决定提出上诉,探索OTC市场交易,并继续对急性髓性白血病的CER-1236疗法的临床开发,早期结果显示T细胞迅速扩张且无毒性. The company plans to appeal the decision, explore OTC Markets trading, and continue clinical development of its CER-1236 therapy for acute myeloid leukemia, where early results showed rapid T cell expansion and no toxicity. 将于2025年10月31日暂停交易。 Trading will be suspended on October 31, 2025.